Caribou Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	12.36	16.29	51.16	58.34	240.42
Short-Term Investments	126.98	193.24	277.67	189.33	135.41
Cash & Short-Term Investments	139.34	209.54	328.83	247.66	375.83
Cash Growth	-33.50%	-36.28%	32.77%	-34.10%	2255.87%
Accounts Receivable	0.07	0.27	0.15	0.2	1.15
Other Receivables	2.91	2.99	3.71	4.46	6.97
Total Trade Receivables	2.98	3.25	3.86	4.66	8.12
Other Current Assets	2.91	6.59	6.16	7.92	7.24
Total Current Assets	145.23	219.38	338.84	260.25	391.19
Net Property, Plant & Equipment	24.43	39.29	40.45	34.91	4.89
Long-Term Investments	3.51	49.13	51.33	77.07	45.3
Other Long-Term Assets	2.2	5.52	1.59	1.54	0.98
Total Assets	175.37	313.31	432.21	373.77	442.36
Accounts Payable	5.78	2.48	3.12	1.15	3.99
Accrued Expenses	16.54	23.62	21.14	16.08	13.14
Current Portion of Leases	1.2	1.43	1.2	0.97	-
Unearned Revenue	1.9	3.13	2.85	9.94	8.7
Total Current Liabilities	25.41	30.65	28.3	28.13	25.83
Long-Term Leases	26.03	25.06	25.91	26.78	2.1
Other Long-Term Liabilities	1.75	4.65	9.6	17.99	26.61
Total Long-Term Liabilities	27.78	29.71	35.51	44.77	28.7
Total Liabilities	53.19	60.36	63.81	72.89	54.53
Shareholders' Equity	122.18	252.95	368.4	300.87	387.83
Total Liabilities & Equity	175.37	313.31	432.21	373.77	442.36
Total Debt	27.23	26.49	27.11	27.75	2.1
Net Cash (Debt)	112.11	183.05	301.72	219.92	373.74
Net Cash Growth	-38.75%	-39.33%	37.20%	-41.16%	2500.08%
Net Cash Per Share	1.20	2.03	4.09	3.62	11.80

Updated Mar 5, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q